Clinical trials: Lichen Simplex Chronicus
Skin Pruritus, Itch
Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel for ultra-rapid relief of moderate-to-severe skin pruritus…
- Conditions
- Skin Pruritus, Itch, Eczema Itch, Neurodermatitis
- Trial name
- HA35-ITCH (NCT07580911)
- Testing
- 10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Anti-Pruritic Gel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nakhia Impex LLC
Lichen Simplex Chronicus
A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of single ascending oral doses(SAD) of PG-033 by directly comparing it with placebo.
- Trial name
- NCT07013097
- Testing
- PG-033
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Prurigo Nodularis
Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.
- Trial name
- NCT04501666
- Testing
- Nemolizumab 30 mg
- Where
- 100 sites in United States, Austria and 8 more
- Volunteers
- 286 people
- Sponsor
- Galderma R&D
Prurigo Nodularis
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
- Trial name
- NCT02196324
- Testing
- serlopitant
- Where
- 15 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Vyne Therapeutics Inc.
Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus
A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Participants with diseases characterized by chronic pruritus experiencing moderate to severe pruritus will be enrolled in this pilot Phase 2 study.
- Conditions
- Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus
- Trial name
- NCT03858634
- Testing
- KPL-716
- Where
- 14 sites in United States
- Volunteers
- 58 people
- Sponsor
- Genentech, Inc.
Neurodermatitis
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Primary Objective: To demonstrate the efficacy of dupilumab on itch response in participants with prurigo nodularis (PN), inadequately controlled on topical prescription therapy or when those therapies are not advisable.
- Trial name
- NCT04202679
- Testing
- Dupilumab SAR231893, Moisturizers, Low to medium potent topical corticosteroids
- Where
- 57 sites in United States, Canada and 9 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Atrophic Vaginitis, Vaginal Atrophy
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
Vulvovaginal skin conditions, namely vaginal atrophy, lichen sclerosus, lichen simplex chronicus and lichen planus affecting the female adult population will be treated with a novel gel dressing to test the short- and long-term…
- Conditions
- Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva
- Trial name
- VALOR (NCT05953090)
- Testing
- 7-0940
- Where
- 14 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Stratpharma AG
Prurigo Nodularis
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.
- Trial name
- NCT04501679
- Testing
- Nemolizumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 274 people
- Sponsor
- Galderma R&D
Lichen Simplex Chronicus
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged…
- Trial name
- NCT06687967
- Testing
- Dupilumab
- Where
- 63 sites in United States, Argentina and 15 more
- Volunteers
- 142 people
- Sponsor
- Sanofi
Atopic Dermatitis, Neurodermatitis
Investigation of Efficacy and Safety of EPOGAM
In this study it will be investigated if patients with atopic dermatitis responding to EPOGAM treatment, show a significant increase of dihomo-gamma-linolic acid in the blood.
- Trial name
- NCT00878670
- Testing
- EPOGAM 1000
- Where
- 2 sites in Switzerland
- Volunteers
- 23 people
- Sponsor
- Max Zeller Soehne AG
Atopic Dermatitis
A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis
This is a multi-center, Phase 1b, double-blind, placebo-controlled, SAD and MAD, first-in-human study in subjects with mild to severe AD receiving si-544. The study consists of 2 parts, an SAD and an MAD part.
- Trial name
- NCT05383378
- Testing
- si-544
- Where
- 5 sites in Germany
- Volunteers
- 36 people
- Sponsor
- selectION Therapeutics GmbH
Neurodermatitis
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
Primary Objective: To demonstrate the efficacy of dupilumab on itch response in participants with prurigo nodularis (PN), inadequately controlled on topical prescription therapies or when those therapies are not advisable.
- Trial name
- NCT04183335
- Testing
- Dupilumab SAR231893, Moisturizers, Low to medium potent topical corticosteroids
- Where
- 63 sites in United States, Argentina and 6 more
- Volunteers
- 151 people
- Sponsor
- Sanofi
Lichen Simplex Chronicus
A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants.
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of multiple ascending oral doses(MAD) of PG-033 by directly comparing it with placebo.
- Trial name
- NCT07619183
- Testing
- PG-033 tablets
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Lichen Simplex Chronicus
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged…
- Trial name
- NCT06687980
- Testing
- Dupilumab
- Where
- 63 sites in United States, Argentina and 15 more
- Volunteers
- 138 people
- Sponsor
- Sanofi